Bio­gen opts in­to De­nali Alzheimer's pro­gram tar­get­ing amy­loid be­ta plaque

Bio­gen is tak­ing an­oth­er step in its neu­rode­gen­er­a­tive dis­ease col­lab­o­ra­tion with De­nali Ther­a­peu­tics.

The big biotech an­nounced Wednes­day it is pick­ing up an op­tion for a pre­clin­i­cal Alzheimer’s pro­gram from De­nali, tak­ing over all de­vel­op­ment ac­tiv­i­ties and costs. In ex­change, De­nali gets some cash — for an undis­closed amount — and the promise of some mile­stones down the road.

Bio­gen and De­nali spokes­peo­ple both de­clined to pro­vide spe­cif­ic fi­nan­cial de­tails for the op­tion pay­ment and mile­stones. Ad­di­tion­al­ly, nei­ther com­pa­ny dis­closed this op­tion’s fi­nan­cials when they signed the col­lab­o­ra­tion in Au­gust 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER